Oligonucleotide Therapeutics Society’s Post

Argenica Therapeutics Explore essential executive insights into Argenica Therapeutics' recent progress in the Phase 2 trial of ARG-007, focusing on safety and operational efficiency. Read More https://lnkd.in/gbzUzpmj #Biotechnology, #ARG007, #clinicalTrial, #executiveInsights, #strategicAnalysis

Influenza A Market is Expected to Expand at a Healthy Growth Rate | Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, and other companies are expected to change the Indication Name Market scenario by 2032, forecasts De https://lnkd.in/eUKcgbWU #marketanalysis #marketresearch #marketresearchreports #businessintelligence

Understand the potential of the difficult-to-express protein market driven by the surging demand for recombinant proteins. Learn more about how innovative therapeutics, exemplified by Amgen Inc.'s Prolia, are shaping the landscape of medical solutions. Dive deeper into the protein market dynamics: https://lnkd.in/gDq7dX22 . . . #difficulttoexpressprotein #recombinantproteins #medicalinnovation #marketgrowth #biotechnology #tbrc #thebusinessresearchcompany #marketresearch #marketintelligence

Great to see #Ariceum profiled in the Spring Edition of European Biotechnology - Life Science and Industry Magazine (EBM).   Read the interesting article, which explores the evolving developments in the #radiopharmaceutical space and highlights the increasing interest from investors and big pharma.   Our CEO, Manfred Ruediger, and CMO, Germo Gericke, provided insights and compared the current state of the radiopharmaceuticals field with the course that checkpoint inhibitors took and their initial successes which in turn have led to a wave of imitators and the emergence of today's state of play.   Article source: European Biotech News!   #lifesciences #biotech #radiopharmaceuticals #satoreotide #ATT001

Did you hear that we recently acquired AbCheck s.r.o.? Learn more about the acquisition and how it boosts our Address, Navigate, Determine (AND)™ Platform and enhances our ability to generate multiple AND-Body™ Therapeutics in parallel: https://bit.ly/47AA18g #Biotechnology #Healthcare #DrugDiscovery #DrugDevelopment

High correct bispecific chain pairing. See how we address production efficiency and cost of goods reduction from the outset for the development of bispecifics.

Published today....@ Nature Communications Here is my equally contributed research article on "Mirror-image ligand discovery enabled by single-shot fast-flow synthesis of D-proteins" in collaboration with FOG pharmaceuticals. #Phage display #Peptide binder # Flow-synthesis # Protein folding https://lnkd.in/ewYWqzU4

February was a month full of exciting news, from outstanding performance of NurExone Biologic (TSXV: NRX) (FSE: J90) to publication of findings that exosomes can carry endocannaninoids. UPDATE: Due to the time difference, the original version of this analysis did not include the latest financial results from Capricor Therapeutics. The PDF has now been updated to reflect this. #extracellularvesicles #exosomes #biotech #pharma #therapies #drugdiscovery #lifescienceindustry #investing #biotechinnovation #investing #BiotechInnovation, #HealthcareSolutions, #StartupGrowth, #MedicalTechnology, #TherapeuticAdvances, #BiomedicalResearch, #InvestInHealth, #LifeSciencesVC, #BiotechFunding, #DisruptiveMedTech

We’re excited to be here at #SLAS2024, and are looking forward to seeing you at Booth #261! Don't forget to stop by our poster to chat with our CEO about our newest #innovation: #cell and #organelle targeted ion channel assays. #ionchannels #HTS #pharmacology #biotechnology #researchanddevelopment #scientificresearch #IONBiosciences

FibroBiologics is set to join the Russell 2000® Index effective July 1, 2024, according to a preliminary list of additions. This milestone reflects our growth and commitment to developing novel therapeutics using fibroblasts. Joining the #Russell2000 marks a significant step in increasing our visibility in the investment community and enhancing shareholder value. For more: https://bit.ly/4cHC6ST #Biotechnology #InvestmentGrowth